Treatment of chronic knee osteoarthritis with Autologous Conditioned Serum
- Conditions
- Osteoarthritis.Erosive (osteo)arthritisM15.4
- Registration Number
- IRCT20160422027520N13
- Lead Sponsor
- Pishtaz teb zaman Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Men and women between the ages of 18 and 75 with OA diagnosis based on the American College of Rheumatology
Analog scale of knee pain (VAS) equal to or greater than 2.5
People with at least 4 months of history of pain or swelling in one or both knees
Radiological classification scale Kellgren-Lawrence 1 or 2
The availability of individual during the study period
BMI Between 20 and 35
People under the age of 18 and over 75 years
Pregnant women or women who are breastfeeding
People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, rheumatoid arthritis, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome
Those linked to acetaminophen or Vicodin or a history of drug misuse
History of cortisone injections in the last 6 weeks
The use of non-steroidal anti-inflammatory drugs 1 week ago
Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ
The use of inhibitors of platelet aggregation and anti-coagulation such as heparin
History of knee surgery in the last 3 months
Extraordinary deformation (varus >5?, valgus >5?)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determining knee pain by VAS in all phases of clinical trial. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of knee function by WOMAC and KOOS in all phases of clinical trial. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Questionnaire (WOMAC), Questionnaire (KOOS).;Determine the range of knee motion by manual joiniometry in all phases of clinical trial. Timepoint: Before injection and 1, 3 and 6 months after the first injection. Method of measurement: Range of motion (Degree).
- Secondary Outcome Measures
Name Time Method